Have you registered for #ASGCT2025? Secure your spot to join us in New Orleans or virtually at the for the premier event in gene and cell therapy.
The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
In Q1 2025:
In the U.S., approvals of Encelto for MacTel type 2 and Qfitlia for hemophilia A or B
In China, approval of Ruiboshen, the country's first mesenchymal stem cell therapy, for steroid-refractory acute graft-versus-host disease
Continued increase—up to 74% from 58%—in non-genetically modified cell therapy trials initiated for non-oncology indications
Read the Full Report
Read all available reports from 2024.
Read all the landscape reports from 2023.
Read all the landscape reports from 2022.
Read all the reports from 2021 here.
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico